Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Kaletra

Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 49–50

HOS-109006 · Präparat HOS-093083

49 Antiarrhythmics Amiodarone, Amiodarone, Dronedarone: Concomitant administration of Dronedarone Concentrations may be increased Kaletra and amiodarone or due to CYP3A4 inhibition by dronedarone is contraindicated (see lopinavir/ritonavir. section 4.3) as the risk of arrhythmias or other serious adverse reactions may be increased. Digoxin Digoxin: Caution is warranted and therapeutic Plasma concentrations may be drug monitoring of digoxin increased due to P-glycoprotein concentrations, if available, is inhibition by lopinavir/ritonavir. recommended in case of The increased digoxin level may co-administration of Kaletra and lessen over time as P-gp digoxin. Particular caution should be induction develops. used when prescribing Kaletra in patients taking digoxin as the acute inhibitory effect of ritonavir on P-gp is expected to significantly increase digoxin levels. Initiation of digoxin in patients already taking Kaletra is likely to result in lower than expected increases of digoxin concentrations. Bepridil, Systemic Bepridil, Systemic Lidocaine, Caution is warranted and therapeutic Lidocaine, and Quinidine: drug concentration monitoring is Quinidine Concentrations may be increased recommended when available. when co-administered with lopinavir/ritonavir. Antibiotics Clarithromycin Clarithromycin: For patients with renal impairment Moderate increases in (CrCL < 30 ml/min) dose reduction clarithromycin AUC are expected of clarithromycin should be due to CYP3A inhibition by considered (see section 4.4). Caution lopinavir/ritonavir. should be exercised in administering clarithromycin with Kaletra to patients with impaired hepatic or renal function. Anticancer agents and kinase inhibitors Abemaciclib Serum concentrations may be Co-administration of abemaciclib increased due to CYP3A and Kaletra should be avoided. If inhibition by ritonavir. this co-administration is judged unavoidable, refer to the abemaciclib SmPC for dosage adjustment recommendations. Monitor for ADRs related to abemaciclib. Apalutamide Apalutamide is a moderate to Decreased exposure of Kaletra may strong CYP3A4 inducer and this result in potential loss of virological may lead to a decreased exposure response. of lopinavir/ritonavir. In addition, co-administration of apalutamide and Kaletra may lead to Serum concentrations of serious adverse events including apalutamide may be increased due seizure due to higher apalutamide to CYP3A inhibition by levels. Concomitant use of Kaletra lopinavir/ritonavir. with apalutamide is not recommended. Afatinib Afatinib: Caution should be exercised in AUC: ↑ administering afatinib with Kaletra. (Ritonavir 200 mg twice Cmax: ↑ Refer to the afatinib SmPC for daily)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) abemaciclib (HOS-086209) lidocaine (HOS-108866) apalutamide (HOS-086212) bepridil (HOS-085612) quinidine (HOS-085593) digoxin (HOS-086172) lead (HOS-085592) afatinib (HOS-086207) clarithromycin (HOS-084517) amiodarone (HOS-085596)